Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Buy
59
TERN Quote, Financials, Valuation and Earnings
Last price:
$37.77
Seasonality move
:
-12.79%
Day range:
$35.45 - $38.03
52-week range:
$1.87 - $48.26
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
11.98x
Volume:
1.8M
Avg. volume:
2.2M
1-year change:
710.52%
Market cap:
$3.4B
Revenue:
--
EPS (TTM):
-$1.03
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TERN
Terns Pharmaceuticals, Inc.
|
-- | -$0.31 | -- | -16.04% | $58.13 |
|
ADMA
ADMA Biologics, Inc.
|
$150.5M | $0.23 | 23.95% | 81.82% | $25.67 |
|
CDTX
Cidara Therapeutics, Inc.
|
-- | -$1.56 | -100% | -71.03% | $221.50 |
|
COGT
Cogent Biosciences, Inc.
|
-- | -$0.51 | -- | -4.86% | $50.75 |
|
CORT
Corcept Therapeutics, Inc.
|
$255.3M | $0.30 | 27.74% | -71.78% | $94.20 |
|
LGND
Ligand Pharmaceuticals, Inc.
|
$55.6M | $1.50 | 29.84% | -74.47% | $243.44 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TERN
Terns Pharmaceuticals, Inc.
|
$37.77 | $58.13 | $3.4B | -- | $0.00 | 0% | -- |
|
ADMA
ADMA Biologics, Inc.
|
$16.43 | $25.67 | $3.9B | 19.30x | $0.00 | 0% | 8.27x |
|
CDTX
Cidara Therapeutics, Inc.
|
$221.38 | $221.50 | $7B | -- | $0.00 | 0% | 55.23x |
|
COGT
Cogent Biosciences, Inc.
|
$37.08 | $50.75 | $5.7B | -- | $0.00 | 0% | 55.99x |
|
CORT
Corcept Therapeutics, Inc.
|
$40.83 | $94.20 | $4.3B | 46.65x | $0.00 | 0% | 6.59x |
|
LGND
Ligand Pharmaceuticals, Inc.
|
$190.44 | $243.44 | $3.7B | 91.66x | $0.00 | 0% | 14.92x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TERN
Terns Pharmaceuticals, Inc.
|
0.36% | 0.081 | 0.16% | 19.21x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -3.277 | 2.38% | 3.53x |
|
CDTX
Cidara Therapeutics, Inc.
|
0.47% | 5.000 | 0.07% | 4.47x |
|
COGT
Cogent Biosciences, Inc.
|
16.68% | 3.084 | 2.86% | 6.28x |
|
CORT
Corcept Therapeutics, Inc.
|
1% | -3.733 | 0.07% | 2.85x |
|
LGND
Ligand Pharmaceuticals, Inc.
|
32.19% | 1.350 | 12.95% | 23.64x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TERN
Terns Pharmaceuticals, Inc.
|
-$111K | -$27.7M | -28.94% | -29.05% | -- | -$19.8M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
CDTX
Cidara Therapeutics, Inc.
|
-$28K | -$43.6M | -68.01% | -68.74% | -3675.83% | -$40.6M |
|
COGT
Cogent Biosciences, Inc.
|
-$1.1M | -$83.4M | -103.58% | -117.99% | -- | -$64.4M |
|
CORT
Corcept Therapeutics, Inc.
|
$203M | $10.2M | 15.84% | 16% | 4.92% | $54.5M |
|
LGND
Ligand Pharmaceuticals, Inc.
|
$103.6M | $54.1M | 5.15% | 5.72% | 46.85% | $4.8M |
Terns Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns TERN or ADMA?
ADMA Biologics, Inc. has a net margin of -- compared to Terns Pharmaceuticals, Inc.'s net margin of 27.14%. Terns Pharmaceuticals, Inc.'s return on equity of -29.05% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital TERNTerns Pharmaceuticals, Inc.-- -$0.27 $285.1M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About TERN or ADMA?
Terns Pharmaceuticals, Inc. has a consensus price target of $58.13, signalling upside risk potential of 53.89%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 56.22%. Given that ADMA Biologics, Inc. has higher upside potential than Terns Pharmaceuticals, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Terns Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TERNTerns Pharmaceuticals, Inc.8 0 0 ADMAADMA Biologics, Inc.3 0 0 -
Is TERN or ADMA More Risky?
Terns Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.502%.
-
Which is a Better Dividend Stock TERN or ADMA?
Terns Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TERN or ADMA?
Terns Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Terns Pharmaceuticals, Inc.'s net income of -$24.6M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Terns Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 19.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals, Inc. is -- versus 8.27x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TERNTerns Pharmaceuticals, Inc.-- -- -- -$24.6M ADMAADMA Biologics, Inc.8.27x 19.30x $134.2M $36.4M
-
Which has Higher Returns TERN or CDTX?
Cidara Therapeutics, Inc. has a net margin of -- compared to Terns Pharmaceuticals, Inc.'s net margin of -30201.66%. Terns Pharmaceuticals, Inc.'s return on equity of -29.05% beat Cidara Therapeutics, Inc.'s return on equity of -68.74%.
Company Gross Margin Earnings Per Share Invested Capital TERNTerns Pharmaceuticals, Inc.-- -$0.27 $285.1M CDTXCidara Therapeutics, Inc.81.53% -$3.10 $424.4M -
What do Analysts Say About TERN or CDTX?
Terns Pharmaceuticals, Inc. has a consensus price target of $58.13, signalling upside risk potential of 53.89%. On the other hand Cidara Therapeutics, Inc. has an analysts' consensus of $221.50 which suggests that it could grow by 0.05%. Given that Terns Pharmaceuticals, Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Terns Pharmaceuticals, Inc. is more attractive than Cidara Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TERNTerns Pharmaceuticals, Inc.8 0 0 CDTXCidara Therapeutics, Inc.0 3 0 -
Is TERN or CDTX More Risky?
Terns Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cidara Therapeutics, Inc. has a beta of 1.561, suggesting its more volatile than the S&P 500 by 56.074%.
-
Which is a Better Dividend Stock TERN or CDTX?
Terns Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cidara Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Cidara Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TERN or CDTX?
Terns Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Cidara Therapeutics, Inc. quarterly revenues of --. Terns Pharmaceuticals, Inc.'s net income of -$24.6M is higher than Cidara Therapeutics, Inc.'s net income of -$83.2M. Notably, Terns Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Cidara Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals, Inc. is -- versus 55.23x for Cidara Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TERNTerns Pharmaceuticals, Inc.-- -- -- -$24.6M CDTXCidara Therapeutics, Inc.55.23x -- -- -$83.2M
-
Which has Higher Returns TERN or COGT?
Cogent Biosciences, Inc. has a net margin of -- compared to Terns Pharmaceuticals, Inc.'s net margin of --. Terns Pharmaceuticals, Inc.'s return on equity of -29.05% beat Cogent Biosciences, Inc.'s return on equity of -117.99%.
Company Gross Margin Earnings Per Share Invested Capital TERNTerns Pharmaceuticals, Inc.-- -$0.27 $285.1M COGTCogent Biosciences, Inc.-- -$0.59 $363M -
What do Analysts Say About TERN or COGT?
Terns Pharmaceuticals, Inc. has a consensus price target of $58.13, signalling upside risk potential of 53.89%. On the other hand Cogent Biosciences, Inc. has an analysts' consensus of $50.75 which suggests that it could grow by 36.87%. Given that Terns Pharmaceuticals, Inc. has higher upside potential than Cogent Biosciences, Inc., analysts believe Terns Pharmaceuticals, Inc. is more attractive than Cogent Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TERNTerns Pharmaceuticals, Inc.8 0 0 COGTCogent Biosciences, Inc.9 2 0 -
Is TERN or COGT More Risky?
Terns Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cogent Biosciences, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.923%.
-
Which is a Better Dividend Stock TERN or COGT?
Terns Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cogent Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Cogent Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TERN or COGT?
Terns Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Cogent Biosciences, Inc. quarterly revenues of --. Terns Pharmaceuticals, Inc.'s net income of -$24.6M is higher than Cogent Biosciences, Inc.'s net income of -$80.9M. Notably, Terns Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Cogent Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals, Inc. is -- versus 55.99x for Cogent Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TERNTerns Pharmaceuticals, Inc.-- -- -- -$24.6M COGTCogent Biosciences, Inc.55.99x -- -- -$80.9M
-
Which has Higher Returns TERN or CORT?
Corcept Therapeutics, Inc. has a net margin of -- compared to Terns Pharmaceuticals, Inc.'s net margin of 9.32%. Terns Pharmaceuticals, Inc.'s return on equity of -29.05% beat Corcept Therapeutics, Inc.'s return on equity of 16%.
Company Gross Margin Earnings Per Share Invested Capital TERNTerns Pharmaceuticals, Inc.-- -$0.27 $285.1M CORTCorcept Therapeutics, Inc.97.79% $0.16 $638.3M -
What do Analysts Say About TERN or CORT?
Terns Pharmaceuticals, Inc. has a consensus price target of $58.13, signalling upside risk potential of 53.89%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $94.20 which suggests that it could grow by 130.71%. Given that Corcept Therapeutics, Inc. has higher upside potential than Terns Pharmaceuticals, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Terns Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TERNTerns Pharmaceuticals, Inc.8 0 0 CORTCorcept Therapeutics, Inc.3 1 1 -
Is TERN or CORT More Risky?
Terns Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.247, suggesting its less volatile than the S&P 500 by 75.347%.
-
Which is a Better Dividend Stock TERN or CORT?
Terns Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TERN or CORT?
Terns Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Corcept Therapeutics, Inc. quarterly revenues of $207.6M. Terns Pharmaceuticals, Inc.'s net income of -$24.6M is lower than Corcept Therapeutics, Inc.'s net income of $19.4M. Notably, Terns Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Corcept Therapeutics, Inc.'s PE ratio is 46.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals, Inc. is -- versus 6.59x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TERNTerns Pharmaceuticals, Inc.-- -- -- -$24.6M CORTCorcept Therapeutics, Inc.6.59x 46.65x $207.6M $19.4M
-
Which has Higher Returns TERN or LGND?
Ligand Pharmaceuticals, Inc. has a net margin of -- compared to Terns Pharmaceuticals, Inc.'s net margin of 10.18%. Terns Pharmaceuticals, Inc.'s return on equity of -29.05% beat Ligand Pharmaceuticals, Inc.'s return on equity of 5.72%.
Company Gross Margin Earnings Per Share Invested Capital TERNTerns Pharmaceuticals, Inc.-- -$0.27 $285.1M LGNDLigand Pharmaceuticals, Inc.89.7% $5.68 $1.4B -
What do Analysts Say About TERN or LGND?
Terns Pharmaceuticals, Inc. has a consensus price target of $58.13, signalling upside risk potential of 53.89%. On the other hand Ligand Pharmaceuticals, Inc. has an analysts' consensus of $243.44 which suggests that it could grow by 27.83%. Given that Terns Pharmaceuticals, Inc. has higher upside potential than Ligand Pharmaceuticals, Inc., analysts believe Terns Pharmaceuticals, Inc. is more attractive than Ligand Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TERNTerns Pharmaceuticals, Inc.8 0 0 LGNDLigand Pharmaceuticals, Inc.6 0 0 -
Is TERN or LGND More Risky?
Terns Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ligand Pharmaceuticals, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock TERN or LGND?
Terns Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ligand Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ligand Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TERN or LGND?
Terns Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Ligand Pharmaceuticals, Inc. quarterly revenues of $115.5M. Terns Pharmaceuticals, Inc.'s net income of -$24.6M is lower than Ligand Pharmaceuticals, Inc.'s net income of $117.3M. Notably, Terns Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Ligand Pharmaceuticals, Inc.'s PE ratio is 91.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals, Inc. is -- versus 14.92x for Ligand Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TERNTerns Pharmaceuticals, Inc.-- -- -- -$24.6M LGNDLigand Pharmaceuticals, Inc.14.92x 91.66x $115.5M $117.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
